Our Current Clinical Trials

We’re actively recruiting patients to participate in clinical trials to evaluate our therapeutic candidates. If you believe you or a loved one might be a good candidate for our trials, we encourage you to reach out directly via the link below.

Inbrx 109

INBRX-109

Our Tetravalent DR5 Agonist

INBRX-109, our most advanced program, is a precisely engineered tetravalent sdAb-based therapeutic candidate that agonizes DR5 to induce tumor selective programmed cell death.

Learn more clinicaltrials.gov
Inbrx 106

INBRX-106

Our Hexavalent OX40 Agonist

INBRX-106 is a hexavalent sdAb-based therapeutic candidate targeting OX40 that provides co-stimulation that promotes T-cell expansion, enhanced effector function and memory cell formation, and prevents activation-induced cell death.

Learn more clinicaltrials.gov
Inbrx 105

INBRX-105

Our PD-L1 x 4-1BB Tetravalent Conditional Agonist

INBRX-105 is a tetravalent sdAb-based therapeutic candidate that acts both as an antagonist of PD-L1 and a conditional agonist of 4-1BB.

Learn more clinicaltrials.gov
Inbrx 101

INBRX-101

Our Recombinant Alpha-1 Anti- trypsin Fc-Fusion Protein (AAT-Fc)

INBRX-101 is a recombinant human AAT-Fc fusion protein therapeutic candidate currently being evaluated for the treatment of AATD. We believe this therapeutic candidate supports a dosing schedule of every three weeks to achieve continuous normal AAT serum concentrations, a significant improvement from patients’ current regimen.

Learn more clinicaltrials.gov